CD28 and neoplasm: In addition, localized or targeted use of anti-CD28 mAbs has much potential such as incorporating the intracellular costimulatory domain of CD28 into CAR (chimeric antigen receptor) T cells for adoptive transfer immunotherapy and the use of CD28 agonist aptamer with tumor vaccine [66,67,68].